CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity - Cytotherapy

Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient - touchONCOLOGY

IJMS, Free Full-Text

WO2020198413A1 - Tn-muc1 chimeric antigen receptor (car) t cell therapy - Google Patents

Haematologica, Volume 108, Issue 8 by Haematologica - Issuu

Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy

Genes, Free Full-Text

Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity - Cytotherapy

Physiological lentiviral vectors for the generation of improved CAR-T cells - ScienceDirect

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion - eBioMedicine

Chimeric antigen receptor T‐cells: Properties, production, and quality control - Ramesh - 2023 - International Journal of Laboratory Hematology - Wiley Online Library

Frontiers Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies